Barclays’s Allarity Therapeutics ALLR Stock Holding History

Barclays’s Portfolio ALLR Stock Details ALLR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,078	Closed	-$9.44K	–	5233
2025 Q1	$9.44K	Buy	+10,078	New	+$10.4K	﹤0.01%	4874
2022 Q4	–	Hold	0	–	-$18K	–	5262
2022 Q3	–	Hold	0	–	–	–	4089

Other funds holding ALLR

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Barclays's ALLR Position: Q2 2025 in Review

Barclays sold out of Allarity Therapeutics (ALLR) in Q2 2025, closing a stake of 10,078 shares — an estimated $9.44K sold.

Barclays first reported a position in ALLR in Q1 2025 and held it in 1 quarter. The position peaked at $9.44K in Q1 2025. 10 funds tracked by Wall St. Rank hold ALLR as of Q2 2025.

Barclays reported no remaining Allarity Therapeutics position as of Q2 2025 after selling out during the quarter.
Barclays sold 10,078 Allarity Therapeutics shares in Q2 2025, an estimated $9.44K.
Barclays first reported a position in Allarity Therapeutics in Q1 2025 and held it in 1 quarter.
Barclays's Allarity Therapeutics position peaked at $9.44K in Q1 2025.
10 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.